Defensins. Natural peptide antibiotics of human neutrophils

T Ganz, M E Selsted, D Szklarek, S S Harwig, K Daher, D F Bainton, R I Lehrer, T Ganz, M E Selsted, D Szklarek, S S Harwig, K Daher, D F Bainton, R I Lehrer

Abstract

We extracted a granule-rich sediment from normal human neutrophils and subjected it to chromatographic, electrophoretic, and functional analysis. The extract contained three small (molecular weight less than 3,500) antibiotic peptides that were named human neutrophil peptide (HNP)-1, HNP-2, and HNP-3, and which will be referred to as "defensins." HNP 1-3, a mixture of the three defensins, killed Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli effectively in vitro when tested in 10 mM phosphate buffer containing certain nutrients, but it had little or no bactericidal activity in nutrient-free buffer. In contrast, the nutrient-free buffer supported a high degree of activity by HNP 1-3 against Cryptococcus neoformans. In addition to its antibacterial and antifungal properties, HNP 1-3 directly inactivated herpes simplex virus, Type 1. Two of the individual purified defensins, HNP-1 and HNP-2, were as microbicidal as the mixture HNP 1-3. HNP-3 was less active than the other defensins against most but not all of the microbes tested. Immunoperoxidase stains revealed HNP 1-3 to have a granular localization in the neutrophil's cytoplasm by light microscopy. Frozen thin section immunogold transmission electron microscopy showed HNP 1-3 to be localized in azurophil granules. These studies define a broad-spectrum antimicrobial system in human neutrophils. The defensin system may operate in conjunction with or independently from oxygen-dependent microbicidal processes to enable human neutrophils to inactivate and destroy potential pathogens.

References

    1. J Mol Biol. 1984 Sep 25;178(3):783-5
    1. J Med Microbiol. 1984 Oct;18(2):173-80
    1. J Biol Chem. 1985 Apr 25;260(8):4579-84
    1. J Virol. 1985 May;54(2):467-72
    1. Infect Immun. 1985 Jul;49(1):202-6
    1. J Clin Invest. 1985 Oct;76(4):1436-9
    1. J Exp Med. 1956 May 1;103(5):589-611
    1. Bacteriol Rev. 1960 Mar;24(1):133-40
    1. Infect Immun. 1979 Mar;23(3):587-91
    1. J Bacteriol. 1966 Feb;91(2):755-62
    1. J Infect Dis. 1966 Dec;116(5):551-65
    1. J Exp Med. 1968 May 1;127(5):927-41
    1. Lab Invest. 1971 Mar;24(3):237-45
    1. J Exp Med. 1971 Oct 1;134(4):907-34
    1. J Clin Invest. 1972 Oct;51(10):2566-72
    1. Infect Immun. 1974 Feb;9(2):337-41
    1. Blood. 1974 Aug;44(2):235-46
    1. Infect Immun. 1974 Sep;10(3):616-23
    1. Infect Immun. 1975 Jun;11(6):1226-34
    1. J Clin Invest. 1975 Nov;56(5):1118-24
    1. Infect Immun. 1976 Sep;14(3):843-7
    1. Infect Immun. 1976 Dec;14(6):1269-75
    1. J Clin Pathol. 1977 Feb;30(2):138-40
    1. Infect Immun. 1977 Apr;16(1):145-51
    1. Science. 1977 Jul 15;197(4300):263-5
    1. Infect Immun. 1977 Aug;17(2):382-8
    1. Infect Immun. 1978 Jan;19(1):131-7
    1. J Biol Chem. 1978 Apr 25;253(8):2664-72
    1. Infect Immun. 1979 Aug;25(2):597-602
    1. J Biol Chem. 1979 Nov 10;254(21):11000-9
    1. Methods Enzymol. 1980;70(A):159-65
    1. Histochem J. 1980 Jul;12(4):381-403
    1. J Clin Invest. 1981 Feb;67(2):352-60
    1. Rev Infect Dis. 1981 May-Jun;3(3):565-98
    1. J Med Microbiol. 1981 Nov;14(4):391-9
    1. Infect Immun. 1982 May;36(2):737-44
    1. Infect Immun. 1982 Jun;36(3):1086-95
    1. J Cell Biol. 1982 Dec;95(3):781-92
    1. Biochem J. 1983 Jan 15;210(1):15-9
    1. Adv Exp Med Biol. 1983;162:5-17
    1. Rev Infect Dis. 1983 Sep-Oct;5(5):843-53
    1. J Cell Biol. 1984 Feb;98(2):748-60
    1. Infect Immun. 1984 Mar;43(3):834-8
    1. Infect Immun. 1984 Jul;45(1):150-4
    1. Contemp Top Immunobiol. 1984;14:283-343
    1. Blood. 1985 Feb;65(2):423-32

Source: PubMed

3
購読する